ABOUT US
CONTACT US
FAQ
PRIVACY POLICY
REFUND AND CANCELLATION
BLOGS
COMPANIES
REPORTS
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Icodec Insulin Market Outlook, In‑Depth Analysis & Forecast to 2031
Published Date: October 2025
|
Report Code: QYRE-Auto-37M19917
Home | Market Reports | Health| Health Conditions| Endocrine Conditions
Global Icodec Insulin Market Outlook In Depth Analysis Forecast to 2031
BUY CHAPTERS

Global Icodec Insulin Market Outlook, In‑Depth Analysis & Forecast to 2031

Code: QYRE-Auto-37M19917
Report
October 2025
Pages:116
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES
FEATURED COMPANIES
Novo Nordisk
Lilly
Sanofi
Gan & Lee Pharmaceuticals
Paijin Biotechnology

Icodec Insulin Market

The global Icodec Insulin market is projected to grow from US$ million in 2024 to US$ million by 2031, at a CAGR of %(2025-2031), driven by critical product segments and diverse end‑use applications, while evolving U.S. tariff policies introduce trade‑cost volatility and supply‑chain uncertainty.
Icodec Insulin is a long-acting insulin analog that is widely used in basal insulin therapy for patients with type 1 and type 2 diabetes. Its structure has been modified so that it forms microcrystals after subcutaneous injection, gradually releasing insulin and providing stable blood sugar control for up to 24 hours. This long-acting property reduces the risk of hypoglycemia, especially the incidence of nocturnal hypoglycemia. Icodec Insulin usually only needs to be injected once a day, and its stable efficacy can maintain blood sugar balance throughout the day regardless of when it is injected.
From a downstream perspective, Hospital accounted for % of 2024 revenue, surging to US$ million by 2031 (CAGR: % from 2025–2031).
Icodec Insulin leading manufacturers including Novo Nordisk, Lilly, Sanofi, Paijin Biotechnology, Gan&Lee Pharmaceuticals, etc., dominate supply; the top five capture approximately % of global revenue, with Novo Nordisk leading 2024 sales at US$ million.
Regional Outlook:
North America rose from US$ million in 2024 to a forecast US$ million by 2031 (CAGR %).
Asia‑Pacific will expand from US$ million to US$ million (CAGR  %), led by China (US$ million in 2024, % share rising to % by 2031), Japan (CAGR %), South Korea (CAGR %), and Southeast Asia (CAGR %).
Europe is set to grow from US$ million to US$ million (CAGR %), with Germany projected to hit US$ million by 2031 (CAGR %).

Report Includes:

This definitive report equips CEOs, marketing directors, and investors with a 360° view of the global Icodec Insulin market, seamlessly integrating production and sales performance across the value chain. It analyzes historical sales volume and revenue sales data (2020–2024) and delivers forecasts through 2031, illuminating demand trends and growth drivers.
By segmenting the market by Type and by Application, the study quantifies volume and value, growth rates, technical innovations, niche opportunities, and substitution risks, and analyzes downstream customers distribution pattern.
Granular regional insights cover five major markets—North America, Europe, APAC, South America, and MEA—with in‑depth analysis of 20+ countries. Each region’s dominant products, competitive landscape, and downstream demand trends are clearly detailed.
Critical competitive intelligence profiles manufacturers—sales volume, revenue, margins, pricing strategies, and major customers—and dissects the top-player positioning across product lines, applications, and regions to reveal strategic strengths.
A concise supply‑chain overview maps upstream suppliers, manufacturing technologies, cost structures, and distribution dynamics to identify strategic gaps and unmet demand.
Market Segmentation

Scope of Icodec Insulin Market Report

Report Metric Details
Report Name Icodec Insulin Market
Segment by Type
  • Long-acting
  • Medium-acting
Segment by Application
  • Hospital
  • Clinic
Sales by Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia) Rest of Europe
  • Nordic Countries
  • Asia-Pacific (China, Japan, South Korea)
  • Southeast Asia (India, Australia)
  • Rest of Asia
  • Latin America (Mexico, Brazil)
  • Rest of Latin America
  • Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company Novo Nordisk, Lilly, Sanofi, Paijin Biotechnology, Gan&Lee Pharmaceuticals
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

  • Chapter 1: Defines the Icodec Insulin study scope, segments the market by Type and by Application, etc, highlights segment size and growth potential.
  • Chapter 2: Offers current market state, projects global revenue and sales to 2031, pinpointing high consumption regions and emerging market catalysts
  • Chapter 3: Dissects the manufacturer landscape—ranks by volume and revenue, analyzes profitability and pricing, maps production bases, details manufacturer performance by product type and evaluates concentration alongside M&A moves.
  • Chapter 4: Unlocks high margin product segments—compares sales, revenue, ASP, and technology differentiators, highlighting growth niches and substitution risks
  • Chapter 5: Targets downstream market opportunities—evaluates sales, revenue, and pricing by Application, identifies emerging use cases, and profiles leading customers by region and by Application.
  • Chapter 6: North America—breaks down sales and revenue by Type, by Application and country, profiles key manufacturers and assesses growth drivers and barriers.
  • Chapter 7: Europe—analyses regional sales, revenue and market by Type, by Application and manufacturers, flagging drivers and barriers.
  • Chapter 8: Asia Pacific—quantifies sales and revenue by Type, by Application, and region/country, profiles top manufacturers, and uncovers high potential expansion areas.
  • Chapter 9: Central & South America—measures sales and revenue by Type, by Application, and country, profiles top manufacturers, and identifies investment opportunities and challenges.
  • Chapter 10: Middle East and Africa—evaluates sales and revenue by Type, by Application, and country, profiles key manufacturers, and outlines investment prospects and market hurdles
  • Chapter 11: Profiles manufacturers in depth—details product specs, sales, revenue, margins; Top manufactures 2024 sales breakdowns by Product type, by Application, by sales region SWOT analysis, and recent strategic developments.
  • Chapter 12: Supply chain—analyses upstream raw materials and suppliers, manufacturing footprint, regional production and cost, regulatory and technology, plus downstream channels and distributor roles.
  • Chapter 13: Market dynamics—explores drivers, restraints, regulatory impacts, and risk mitigation strategies.
  • Chapter 15: Actionable conclusions and strategic recommendations.
  • Why This Report:
  • Beyond standard market data, this analysis provides a clear profitability roadmap—empowering you to:
  • Allocate capital strategically to high growth regions (Chapters 6–10) and margin rich segments (Chapter 5).
  • Negotiate from strength with suppliers (Chapter 12) and customers (Chapter5) using cost and demand intelligence.
  • Outmaneuver competitors with granular insights into their operations, margins, and strategies (Chapters 3 and 11).
  • Secure your supply chain against disruptions through upstream and downstream visibility (Chapters 12 and 13).
  • Leverage this 360° intelligence to turn market complexity into actionable competitive advantage.

FAQ for this report

Who are the main players in the Icodec Insulin Market report?

Ans: The main players in the Icodec Insulin Market are Novo Nordisk, Lilly, Sanofi, Paijin Biotechnology, Gan&Lee Pharmaceuticals

What are the Application segmentation covered in the Icodec Insulin Market report?

Ans: The Applications covered in the Icodec Insulin Market report are Hospital, Clinic

What are the Type segmentation covered in the Icodec Insulin Market report?

Ans: The Types covered in the Icodec Insulin Market report are Long-acting, Medium-acting

1 Study Coverage
1.1 Introduction to Icodec Insulin: Definition, Properties, and Key Attributes
1.2 Market Segmentation by Type
1.2.1 Global Icodec Insulin Market Size by Type, 2020 VS 2024 VS 2031
1.2.2 Long-acting
1.2.3 Medium-acting
1.3 Market Segmentation by Application
1.3.1 Global Icodec Insulin Market Size by Application, 2020 VS 2024 VS 2031
1.3.2 Hospital
1.3.3 Clinic
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Executive Summary
2.1 Global Icodec Insulin Revenue Estimates and Forecasts 2020-2031
2.2 Global Icodec Insulin Revenue by Region
2.2.1 Revenue Comparison: 2020 VS 2024 VS 2031
2.2.2 Historical and Forecasted Revenue by Region (2020--2031)
2.2.3 Global Revenue Market Share by Region (2020-2031)
2.3 Global Icodec Insulin Sales Estimates and Forecasts 2020-2031
2.4 Global Icodec Insulin Sales by Region
2.4.1 Sales Comparison: 2020 VS 2024 VS 2031
2.4.2 Historical and Forecasted Sales by Region (2020-2031)
2.4.3 Emerging Market Focus: Growth Drivers & Investment Trends
2.4.4 Global Sales Market Share by Region (2020-2031)
3 Competition by Manufacturers
3.1 Global Icodec Insulin Sales by Manufacturers
3.1.1 Global Sales Volume by Manufacturers (2020-2025)
3.1.2 Global Top 5 and Top 10 Manufacturers’Market Share by Sales Volume (2024)
3.2 Global Icodec Insulin Manufacturer Revenue Rankings and Tiers
3.2.1 Global Revenue (Value) by Manufacturers (2020-2025)
3.2.2 Global Key Manufacturer Revenue Ranking (2023 vs. 2024)
3.2.3 Revenue-Based Tier Segmentation (Tier 1, Tier 2, and Tier 3)
3.3 Manufacturer Profitability Profiles and Pricing Strategies
3.3.1 Gross Margin by Top Manufacturer (2020 VS 2024)
3.3.2 Manufacturer-Level Price Trends (2020-2025)
3.4 Key Manufacturers Manufacturing Base and Headquarters
3.5 Main Product Type Market Size by Manufacturers
3.5.1 Long-acting Market Size by Manufacturers
3.5.2 Medium-acting Market Size by Manufacturers
3.6 Global Icodec Insulin Market Concentration and Dynamics
3.6.1 Global Market Concentration (CR5 and HHI)
3.6.2 Entrant/Exit Impact Analysis
3.6.3 Strategic Moves: M&A, Capacity Expansion, R&D Investment
4 Global Product Segmentation Analysis
4.1 Global Icodec Insulin Sales Performance by Type
4.1.1 Global Historical and Forecasted Sales by Type (2020-2031)
4.1.2 Global Sales Market Share by Type (2020-2031)
4.2 Global Icodec Insulin Revenue Trends by Type
4.2.1 Global Historical and Forecasted Revenue by Type (2020-2031)
4.2.2 Global Revenue Market Share by Type (2020-2031)
4.3 Global Average Selling Price (ASP) Trends by Type (2020-2031)
4.4 Product Technology Differentiation
4.5 Subtype Dynamics: Growth Leaders, Profitability and Risk
4.5.1 High-Growth Niches and Adoption Drivers
4.5.2 Profitability Hotspots and Cost Drivers
4.5.3 Substitution Threats
5 Global Downstream Application Analysis
5.1 Global Icodec Insulin Sales by Application
5.1.1 Global Historical and Forecasted Sales by Application (2020-2031)
5.1.2 Global Sales Market Share by Application (2020-2031)
5.1.3 High-Growth Application Identification
5.1.4 Emerging Application Case Studies
5.2 Global Icodec Insulin Revenue by Application
5.2.1 Global Historical and Forecasted Revenue by Application (2020-2031)
5.2.2 Revenue Market Share by Application (2020-2031)
5.3 Global Pricing Dynamics by Application (2020-2031)
5.4 Downstream Customer Analysis
5.4.1 Top Customers by Region
5.4.2 Top Customers by Application
6 North America
6.1 North America Sales Volume and Revenue (2020-2031)
6.2 North America Key Manufacturers Sales Revenue in 2024
6.3 North America Icodec Insulin Sales and Revenue by Type (2020-2031)
6.4 North America Icodec Insulin Sales and Revenue by Application (2020-2031)
6.5 North America Growth Accelerators and Market Barriers
6.6 North America Icodec Insulin Market Size by Country
6.6.1 North America Revenue by Country
6.6.2 North America Sales Trends by Country
6.6.3 US
6.6.4 Canada
6.6.5 Mexico
7 Europe
7.1 Europe Sales Volume and Revenue (2020-2031)
7.2 Europe Key Manufacturers Sales Revenue in 2024
7.3 Europe Icodec Insulin Sales and Revenue by Type (2020-2031)
7.4 Europe Icodec Insulin Sales and Revenue by Application (2020-2031)
7.5 Europe Growth Accelerators and Market Barriers
7.6 Europe Icodec Insulin Market Size by Country
7.6.1 Europe Revenue by Country
7.6.2 Europe Sales Trends by Country
7.6.3 Germany
7.6.4 France
7.6.5 U.K.
7.6.6 Italy
7.6.7 Russia
8 Asia-Pacific
8.1 Asia-Pacific Sales Volume and Revenue (2020-2031)
8.2 Asia-Pacific Key Manufacturers Sales Revenue in 2024
8.3 Asia-Pacific Icodec Insulin Sales and Revenue by Type (2020-2031)
8.4 Asia-Pacific Icodec Insulin Sales and Revenue by Application (2020-2031)
8.5 Asia-Pacific Icodec Insulin Market Size by Region
8.5.1 Asia-Pacific Revenue by Region
8.5.2 Asia-Pacific Sales Trends by Region
8.6 Asia-Pacific Growth Accelerators and Market Barriers
8.7 Southeast Asia
8.7.1 Southeast Asia Revenue by Country (2020 VS 2024 VS 2031)
8.7.2 Key Country Analysis: Indonesia, Vietnam, Thailand, Malaysia, Philippines
8.8 China
8.9 Japan
8.10 South Korea
8.11 China Taiwan
8.12 India
9 Central and South America
9.1 Central and South America Sales Volume and Revenue (2020-2031)
9.2 Central and South America Key Manufacturers Sales Revenue in 2024
9.3 Central and South America Icodec Insulin Sales and Revenue by Type (2020-2031)
9.4 Central and South America Icodec Insulin Sales and Revenue by Application (2020-2031)
9.5 Central and South America Investment Opportunities and Key Challenges
9.6 Central and South America Icodec Insulin Market Size by Country
9.6.1 Central and South America Revenue Trends by Country (2020 VS 2024 VS 2031)
9.6.2 Brazil
9.6.3 Argentina
10 Middle East and Africa
10.1 Middle East and Africa Sales Volume and Revenue (2020-2031)
10.2 Middle East and Africa Key Manufacturers Sales Revenue in 2024
10.3 Middle East and Africa Icodec Insulin Sales and Revenue by Type (2020-2031)
10.4 Middle East and Africa Icodec Insulin Sales and Revenue by Application (2020-2031)
10.5 Middle East and Africa Investment Opportunities and Key Challenges
10.6 Middle East and Africa Icodec Insulin Market Size by Country
10.6.1 Middle East and Africa Revenue Trends by Country (2020 VS 2024 VS 2031)
10.6.2 GCC Countries
10.6.3 Turkey
10.6.4 Egypt
10.6.5 South Africa
11 Corporate Profile
11.1 Novo Nordisk
11.1.1 Novo Nordisk Corporation Information
11.1.2 Novo Nordisk Business Overview
11.1.3 Novo Nordisk Icodec Insulin Product Models, Descriptions and Specifications
11.1.4 Novo Nordisk Icodec Insulin Sales, Price, Revenue and Gross Margin (2020-2025)
11.1.5 Novo Nordisk Icodec Insulin Sales by Product in 2024
11.1.6 Novo Nordisk Icodec Insulin Sales by Application in 2024
11.1.7 Novo Nordisk Icodec Insulin Sales by Geographic Area in 2024
11.1.8 Novo Nordisk Icodec Insulin SWOT Analysis
11.1.9 Novo Nordisk Recent Developments
11.2 Lilly
11.2.1 Lilly Corporation Information
11.2.2 Lilly Business Overview
11.2.3 Lilly Icodec Insulin Product Models, Descriptions and Specifications
11.2.4 Lilly Icodec Insulin Sales, Price, Revenue and Gross Margin (2020-2025)
11.2.5 Lilly Icodec Insulin Sales by Product in 2024
11.2.6 Lilly Icodec Insulin Sales by Application in 2024
11.2.7 Lilly Icodec Insulin Sales by Geographic Area in 2024
11.2.8 Lilly Icodec Insulin SWOT Analysis
11.2.9 Lilly Recent Developments
11.3 Sanofi
11.3.1 Sanofi Corporation Information
11.3.2 Sanofi Business Overview
11.3.3 Sanofi Icodec Insulin Product Models, Descriptions and Specifications
11.3.4 Sanofi Icodec Insulin Sales, Price, Revenue and Gross Margin (2020-2025)
11.3.5 Sanofi Icodec Insulin Sales by Product in 2024
11.3.6 Sanofi Icodec Insulin Sales by Application in 2024
11.3.7 Sanofi Icodec Insulin Sales by Geographic Area in 2024
11.3.8 Sanofi Icodec Insulin SWOT Analysis
11.3.9 Sanofi Recent Developments
11.4 Paijin Biotechnology
11.4.1 Paijin Biotechnology Corporation Information
11.4.2 Paijin Biotechnology Business Overview
11.4.3 Paijin Biotechnology Icodec Insulin Product Models, Descriptions and Specifications
11.4.4 Paijin Biotechnology Icodec Insulin Sales, Price, Revenue and Gross Margin (2020-2025)
11.4.5 Paijin Biotechnology Icodec Insulin Sales by Product in 2024
11.4.6 Paijin Biotechnology Icodec Insulin Sales by Application in 2024
11.4.7 Paijin Biotechnology Icodec Insulin Sales by Geographic Area in 2024
11.4.8 Paijin Biotechnology Icodec Insulin SWOT Analysis
11.4.9 Paijin Biotechnology Recent Developments
11.5 Gan&Lee Pharmaceuticals
11.5.1 Gan&Lee Pharmaceuticals Corporation Information
11.5.2 Gan&Lee Pharmaceuticals Business Overview
11.5.3 Gan&Lee Pharmaceuticals Icodec Insulin Product Models, Descriptions and Specifications
11.5.4 Gan&Lee Pharmaceuticals Icodec Insulin Sales, Price, Revenue and Gross Margin (2020-2025)
11.5.5 Gan&Lee Pharmaceuticals Icodec Insulin Sales by Product in 2024
11.5.6 Gan&Lee Pharmaceuticals Icodec Insulin Sales by Application in 2024
11.5.7 Gan&Lee Pharmaceuticals Icodec Insulin Sales by Geographic Area in 2024
11.5.8 Gan&Lee Pharmaceuticals Icodec Insulin SWOT Analysis
11.5.9 Gan&Lee Pharmaceuticals Recent Developments
12 Value Chain and Supply-Chain Analysis
12.1 Icodec Insulin Industry Chain
12.2 Icodec Insulin Upstream Materials Analysis
12.2.1 Raw Materials
12.2.2 Key Suppliers Market Share & Risk Assessment
12.3 Icodec Insulin Integrated Production Analysis
12.3.1 Manufacturing Footprint Analysis
12.3.2 Regional Production Market Share (2020-2031)
12.3.3 Regulatory and Trade Policy Impact on Production
12.3.4 Production Technology Overview
12.3.5 Regional Cost Drivers
12.4 Icodec Insulin Sales Channels and Distribution Networks
12.4.1 Sales Channels
12.4.2 Distributors
13 Icodec Insulin Market Dynamics
13.1 Industry Trends and Evolution
13.2 Market Growth Drivers and Emerging Opportunities
13.3 Market Challenges, Risks, and Restraints
14 Key Findings in the Global Icodec Insulin Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.1.1 Research Programs/Design
15.1.1.2 Market Size Estimation
15.1.1.3 Market Breakdown and Data Triangulation
15.1.2 Data Source
15.1.2.1 Secondary Sources
15.1.2.2 Primary Sources
15.2 Author Details
FEATURED COMPANIES
Novo Nordisk
Lilly
Sanofi
Gan & Lee Pharmaceuticals
Paijin Biotechnology
List of Tables
 Table 1. Global Icodec Insulin Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
 Table 2. Global Icodec Insulin Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
 Table 3. Global Icodec Insulin Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
 Table 4. Global Icodec Insulin Revenue by Region (2020-2025) & (US$ Million)
 Table 5. Global Icodec Insulin Revenue by Region (2026-2031) & (US$ Million)
 Table 6. Global Icodec Insulin Sales Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (K Dose)
 Table 7. Global Icodec Insulin Sales by Region (2020-2025) & (K Dose)
 Table 8. Global Icodec Insulin Sales by Region (2026-2031) & (K Dose)
 Table 9. Emerging Market Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
 Table 10. Global Icodec Insulin Sales by Manufacturers (2020-2025) & (K Dose)
 Table 11. Global Icodec Insulin Sales Share by Manufacturers (2020-2025)
 Table 12. Global Icodec Insulin Revenue by Manufacturers (2020-2025) & (US$ Million)
 Table 13. Global Icodec Insulin Revenue Market Share by Manufacturers (2020-2025)
 Table 14. Global Key Manufacturers’Ranking Shift (2023 vs. 2024) (Based on Revenue)
 Table 15. Global Icodec Insulin by Manufacturer Tier (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Icodec Insulin as of 2024)
 Table 16. Global Icodec Insulin Average Gross Margin (%) by Manufacturer (2020 VS 2024)
 Table 17. Global Icodec Insulin Average Selling Price (ASP) by Manufacturers (2020-2025) & (US$/Dose)
 Table 18. Key Manufacturers Icodec Insulin Manufacturing Base and Headquarters
 Table 19. Global Icodec Insulin Market Concentration Ratio (CR5 and HHI)
 Table 20. Key Market Entrant/Exit (2020-2024) – Drivers & Impact Analysis
 Table 21. Key Mergers & Acquisitions, Expansion Plans, R&D Investment
 Table 22. Global Icodec Insulin Sales by Type (2020-2025) & (K Dose)
 Table 23. Global Icodec Insulin Sales by Type (2026-2031) & (K Dose)
 Table 24. Global Icodec Insulin Revenue by Type (2020-2025) & (US$ Million)
 Table 25. Global Icodec Insulin Revenue by Type (2026-2031) & (US$ Million)
 Table 26. Global Icodec Insulin ASP by Type (2020-2031) & (US$/Dose)
 Table 27. Technical Specifications by Key Product Type
 Table 28. Global Icodec Insulin Sales by Application (2020-2025) & (K Dose)
 Table 29. Global Icodec Insulin Sales by Application (2026-2031) & (K Dose)
 Table 30. Icodec Insulin High-Growth Sectors Demand CAGR (2024-2031)
 Table 31. Global Icodec Insulin Revenue by Application (2020-2025) & (US$ Million)
 Table 32. Global Icodec Insulin Revenue by Application (2026-2031) & (US$ Million)
 Table 33. Global Icodec Insulin ASP by Application (2020-2031) & (US$/Dose)
 Table 34. Top Customers by Region
 Table 35. Top Customers by Application
 Table 36. North America Icodec Insulin Growth Accelerators and Market Barriers
 Table 37. North America Icodec Insulin Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
 Table 38. North America Icodec Insulin Sales (K Dose) by Country (2020 VS 2024 VS 2031)
 Table 39. Europe Icodec Insulin Growth Accelerators and Market Barriers
 Table 40. Europe Icodec Insulin Revenue Grow Rate (CAGR) by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 41. Europe Icodec Insulin Sales (K Dose) by Country (2020 VS 2024 VS 2031)
 Table 42. Asia-Pacific Icodec Insulin Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
 Table 43. Asia-Pacific Icodec Insulin Sales (K Dose) by Country (2020 VS 2024 VS 2031)
 Table 44. Asia-Pacific Icodec Insulin Growth Accelerators and Market Barriers
 Table 45. Southeast Asia Icodec Insulin Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
 Table 46. Central and South America Icodec Insulin Investment Opportunities and Key Challenges
 Table 47. Central and South America Icodec Insulin Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
 Table 48. Middle East and Africa Icodec Insulin Investment Opportunities and Key Challenges
 Table 49. Middle East and Africa Icodec Insulin Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
 Table 50. Novo Nordisk Corporation Information
 Table 51. Novo Nordisk Description and Major Businesses
 Table 52. Novo Nordisk Product Models, Descriptions and Specifications
 Table 53. Novo Nordisk Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2020-2025)
 Table 54. Novo Nordisk Sales Value Proportion by Product in 2024
 Table 55. Novo Nordisk Sales Value Proportion by Application in 2024
 Table 56. Novo Nordisk Sales Value Proportion by Geographic Area in 2024
 Table 57. Novo Nordisk Icodec Insulin SWOT Analysis
 Table 58. Novo Nordisk Recent Developments
 Table 59. Lilly Corporation Information
 Table 60. Lilly Description and Major Businesses
 Table 61. Lilly Product Models, Descriptions and Specifications
 Table 62. Lilly Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2020-2025)
 Table 63. Lilly Sales Value Proportion by Product in 2024
 Table 64. Lilly Sales Value Proportion by Application in 2024
 Table 65. Lilly Sales Value Proportion by Geographic Area in 2024
 Table 66. Lilly Icodec Insulin SWOT Analysis
 Table 67. Lilly Recent Developments
 Table 68. Sanofi Corporation Information
 Table 69. Sanofi Description and Major Businesses
 Table 70. Sanofi Product Models, Descriptions and Specifications
 Table 71. Sanofi Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2020-2025)
 Table 72. Sanofi Sales Value Proportion by Product in 2024
 Table 73. Sanofi Sales Value Proportion by Application in 2024
 Table 74. Sanofi Sales Value Proportion by Geographic Area in 2024
 Table 75. Sanofi Icodec Insulin SWOT Analysis
 Table 76. Sanofi Recent Developments
 Table 77. Paijin Biotechnology Corporation Information
 Table 78. Paijin Biotechnology Description and Major Businesses
 Table 79. Paijin Biotechnology Product Models, Descriptions and Specifications
 Table 80. Paijin Biotechnology Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2020-2025)
 Table 81. Paijin Biotechnology Sales Value Proportion by Product in 2024
 Table 82. Paijin Biotechnology Sales Value Proportion by Application in 2024
 Table 83. Paijin Biotechnology Sales Value Proportion by Geographic Area in 2024
 Table 84. Paijin Biotechnology Icodec Insulin SWOT Analysis
 Table 85. Paijin Biotechnology Recent Developments
 Table 86. Gan&Lee Pharmaceuticals Corporation Information
 Table 87. Gan&Lee Pharmaceuticals Description and Major Businesses
 Table 88. Gan&Lee Pharmaceuticals Product Models, Descriptions and Specifications
 Table 89. Gan&Lee Pharmaceuticals Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2020-2025)
 Table 90. Gan&Lee Pharmaceuticals Sales Value Proportion by Product in 2024
 Table 91. Gan&Lee Pharmaceuticals Sales Value Proportion by Application in 2024
 Table 92. Gan&Lee Pharmaceuticals Sales Value Proportion by Geographic Area in 2024
 Table 93. Gan&Lee Pharmaceuticals Icodec Insulin SWOT Analysis
 Table 94. Gan&Lee Pharmaceuticals Recent Developments
 Table 95. Key Raw Materials Distribution
 Table 96. Raw Materials Key Suppliers
 Table 97. Critical Raw Material Supplier Concentration (2024) & Risk Index
 Table 98. Milestones in Production Technology Evolution
 Table 99. Distributors List
 Table 100. Market Trends and Market Evolution
 Table 101. Market Drivers and Opportunities
 Table 102. Market Challenges, Risks, and Restraints
 Table 103. Research Programs/Design for This Report
 Table 104. Key Data Information from Secondary Sources
 Table 105. Key Data Information from Primary Sources


List of Figures
 Figure 1. Icodec Insulin Product Picture
 Figure 2. Global Icodec Insulin Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
 Figure 3. Long-acting Product Picture
 Figure 4. Medium-acting Product Picture
 Figure 5. Global Icodec Insulin Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
 Figure 6. Hospital
 Figure 7. Clinic
 Figure 8. Icodec Insulin Report Years Considered
 Figure 9. Global Icodec Insulin Revenue, (US$ Million), 2020 VS 2024 VS 2031
 Figure 10. Global Icodec Insulin Revenue (2020-2031) & (US$ Million)
 Figure 11. Global Icodec Insulin Revenue (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
 Figure 12. Global Icodec Insulin Revenue Market Share by Region (2020-2031)
 Figure 13. Global Icodec Insulin Sales (2020-2031) & (K Dose)
 Figure 14. Global Icodec Insulin Sales (CAGR) by Region (2020-2031) (K Dose)
 Figure 15. Global Icodec Insulin Sales Market Share by Region (2020-2031)
 Figure 16. Top 5 and Top 10 Manufacturers Icodec Insulin Sales Volume Market Share in 2024
 Figure 17. Global Icodec Insulin Revenue Market Share Ranking (2024)
 Figure 18. Tier Distribution by Revenue Contribution (2020 VS 2024)
 Figure 19. Long-acting Revenue Market Share by Manufacturer in 2024
 Figure 20. Medium-acting Revenue Market Share by Manufacturer in 2024
 Figure 21. Global Icodec Insulin Sales Market Share by Type (2020-2031)
 Figure 22. Global Icodec Insulin Revenue Market Share by Type (2020-2031)
 Figure 23. Global Icodec Insulin Sales Market Share by Application (2020-2031)
 Figure 24. Global Icodec Insulin Revenue Market Share by Application (2020-2031)
 Figure 25. North America Icodec Insulin Sales YoY (2020-2031) & (K Dose)
 Figure 26. North America Icodec Insulin Revenue YoY (2020-2031) & (US$ Million)
 Figure 27. North America Top 5 Manufacturers Icodec Insulin Sales Revenue (US$ Million) in 2024
 Figure 28. North America Icodec Insulin Sales Volume (K Dose) by Type (2020- 2031)
 Figure 29. North America Icodec Insulin Sales Revenue (US$ Million) by Type (2020 - 2031)
 Figure 30. North America Icodec Insulin Sales Volume (K Dose) by Application (2020-2031)
 Figure 31. North America Icodec Insulin Sales Revenue (US$ Million) by Application (2020-2031)
 Figure 32. US Icodec Insulin Revenue (2020-2031) & (US$ Million)
 Figure 33. Canada Icodec Insulin Revenue (2020-2031) & (US$ Million)
 Figure 34. Mexico Icodec Insulin Revenue (2020-2031) & (US$ Million)
 Figure 35. Europe Icodec Insulin Sales YoY (2020-2031) & (K Dose)
 Figure 36. Europe Icodec Insulin Revenue YoY (2020-2031) & (US$ Million)
 Figure 37. Europe Top 5 Manufacturers Icodec Insulin Sales Revenue (US$ Million) in 2024
 Figure 38. Europe Icodec Insulin Sales Volume (K Dose) by Type (2020-2031)
 Figure 39. Europe Icodec Insulin Sales Revenue (US$ Million) by Type (2020-2031)
 Figure 40. Europe Icodec Insulin Sales Volume (K Dose) by Application (2020-2031)
 Figure 41. Europe Icodec Insulin Sales Revenue (US$ Million) by Application (2020-2031)
 Figure 42. Germany Icodec Insulin Revenue (2020-2031) & (US$ Million)
 Figure 43. France Icodec Insulin Revenue (2020-2031) & (US$ Million)
 Figure 44. U.K. Icodec Insulin Revenue (2020-2031) & (US$ Million)
 Figure 45. Italy Icodec Insulin Revenue (2020-2031) & (US$ Million)
 Figure 46. Russia Icodec Insulin Revenue (2020-2031) & (US$ Million)
 Figure 47. Asia-Pacific Icodec Insulin Sales YoY (2020-2031) & (K Dose)
 Figure 48. Asia-Pacific Icodec Insulin Revenue YoY (2020-2031) & (US$ Million)
 Figure 49. Asia-Pacific Top 8 Manufacturers Icodec Insulin Sales Revenue (US$ Million) in 2024
 Figure 50. Asia-Pacific Icodec Insulin Sales Volume (K Dose) by Type (2020- 2031)
 Figure 51. Asia-Pacific Icodec Insulin Sales Revenue (US$ Million) by Type (2020- 2031)
 Figure 52. Asia-Pacific Icodec Insulin Sales Volume (K Dose) by Application (2020-2031)
 Figure 53. Asia-Pacific Icodec Insulin Sales Revenue (US$ Million) by Application (2020-2031)
 Figure 54. Indonesia Icodec Insulin Revenue (2020-2031) & (US$ Million)
 Figure 55. Japan Icodec Insulin Revenue (2020-2031) & (US$ Million)
 Figure 56. South Korea Icodec Insulin Revenue (2020-2031) & (US$ Million)
 Figure 57. China Taiwan Icodec Insulin Revenue (2020-2031) & (US$ Million)
 Figure 58. India Icodec Insulin Revenue (2020-2031) & (US$ Million)
 Figure 59. Central and South America Icodec Insulin Sales YoY (2020-2031) & (K Dose)
 Figure 60. Central and South America Icodec Insulin Revenue YoY (2020-2031) & (US$ Million)
 Figure 61. Central and South America Top 5 Manufacturers Icodec Insulin Sales Revenue (US$ Million) in 2024
 Figure 62. Central and South America Icodec Insulin Sales Volume (K Dose) by Type (2021-2031)
 Figure 63. Central and South America Icodec Insulin Sales Revenue (US$ Million) by Type (2020-2031)
 Figure 64. Central and South America Icodec Insulin Sales Volume (K Dose) by Application (2020-2031)
 Figure 65. Central and South America Icodec Insulin Sales Revenue (US$ Million) by Application (2020-2031)
 Figure 66. Brazil Icodec Insulin Revenue (2020-2025) & (US$ Million)
 Figure 67. Argentina Icodec Insulin Revenue (2020-2025) & (US$ Million)
 Figure 68. Middle East, and Africa Icodec Insulin Sales YoY (2020-2031) & (K Dose)
 Figure 69. Middle East and Africa Icodec Insulin Revenue YoY (2020-2031) & (US$ Million)
 Figure 70. Middle East and Africa Top 5 Manufacturers Icodec Insulin Sales Revenue (US$ Million) in 2024
 Figure 71. Middle East and Africa Icodec Insulin Sales Volume (K Dose) by Type (2021-2031)
 Figure 72. South America Icodec Insulin Sales Revenue (US$ Million) by Type (2020-2031)
 Figure 73. Middle East and Africa Icodec Insulin Sales Volume (K Dose) by Application (2020-2031)
 Figure 74. Middle East and Africa Icodec Insulin Sales Revenue (US$ Million) by Application (2020-2031)
 Figure 75. GCC Countries Icodec Insulin Revenue (2020-2025) & (US$ Million)
 Figure 76. Turkey Icodec Insulin Revenue (2020-2025) & (US$ Million)
 Figure 77. Egypt Icodec Insulin Revenue (2020-2025) & (US$ Million)
 Figure 78. South Africa Icodec Insulin Revenue (2020-2025) & (US$ Million)
 Figure 79. Icodec Insulin Industry Chain Mapping
 Figure 80. Regional Icodec Insulin Manufacturing Base Distribution (%)
 Figure 81. Global Icodec Insulin Production Market Share by Region (2020-2031)
 Figure 82. Icodec Insulin Production Process
 Figure 83. Regional Icodec Insulin Production Cost Structure
 Figure 84. Channels of Distribution (Direct Vs Distribution)
 Figure 85. Bottom-up and Top-down Approaches for This Report
 Figure 86. Data Triangulation
 Figure 87. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic (PDF)

$4900

This license allows only one user to access the PDF.
Electronic (PDF)

$7350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together
Electronic (PDF)

$9800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (15% Discount)
INQUIRE FOR DISCOUNT

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Strategic Venue Partners

SIMILAR REPORTS

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Call
Buy Now
REQUEST FREE SAMPLE REPORT
Support Contacts
U.S. (TOLL FREE)
+1 (425) 388-2538
THE COMPANY
OUR PRODUCTS
CUSTOMER SUPPORT
POLICES
THE COMPANY
CUSTOMER SUPPORT
OUR PRODUCTS
POLICES
Copyright © 2018 Valuates.com. All Rights Reserved.
Sitemap - Privacy Policy - Terms & Conditions